Importantly, upregulated BCR-ABL expression has been observed in accelerated and blast phase of CML (58–60), as well as under drug treatment (61), which may allow for strong responses mediated by T9141-transduced T cells. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.